Proactive Investors - Run By Investors For Investors
Why invest in ATE?
Antibe Therapeutics: DEEP DIVE

Antibe Therapeutics is poised to disrupt the global pain management industry

The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
OVERVIEW: ATE The Big Picture
ATB-346 is targeting acute and chronic pain associated with osteoarthritis
  • Proprietary hydrogen sulfide technology poised to significantly change the way pain and inflammation is treated

  • Lead drug ATB-346 has proven to reduce ulcer-causing inflammation compared to naproxen

  • Phase 2B study underway with results expected in mid-2019

  • Expert management team with Nobel laureate board members

Who is Antibe Therapeutics?

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) has an ambitious vision to deliver game-changing therapeutics for pain and inflammation.

The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused using non-steroidal anti-inflammatory drugs known as NSAIDs, which are currently the primary therapy for pain relief.

Its lead drug, ATB-346, is targeting acute and chronic pain associated with osteoarthritis. Currently in Phase 2 trials, the drug is a naproxen-derivative that has been shown to deliver pain relief with significantly less gastrointestinal damage than typical NSAID usage.

CEO Dan Legault is an entrepreneur with extensive experience leading early-stage companies. He joined Antibe in 2005 and assembled an expert team of advisors and board members over the last 14 years, including pharmacologist Dr. Louis Ignarro, a Nobel laureate for his work in demonstrating the signaling properties of nitric oxide.

With clinical results to back up the science and the expertise to advance the company, Antibe is ready to take on the global NSAID manufacturers.


NSAIDs are among the most widely used drugs in the world, but the side effects of repeated usage can be intense and ultimately debilitating.

Most NSAIDs are known by their commonly-used brand names like naproxen (Aleve), ibuprofen (Advil) and Asprin.

According to information provided by Antibe, global NSAID sales top $11 billion annually.

Of the 16 drugs to reach $1 billion in sales in the first year on the market, two were for GI-toxicity issues related to NSAIDs. Pharmacia’s Celebrex achieved US$2.3 billion its first year of sales, followed closely by Merck’s Vioxx, which sold around US$1.5 billion.

The game-changer: ATB-346

ATB-346 targets mild to moderate pain relief that arises from a range of conditions, designed to deliver both gastrointestinal and cardiovascular safety with non-addictive pain relief. The drug is a unique anti-inflammatory that releases hydrogen sulfide, which unlike other NSAIDs does not cause GI damage and has no significant effect on blood pressure.

In clinical trials, ATB-346 exhibited an ulceration rate of 2.5% versus 42.1% of participants using naproxen over the two-week treatment period.

Antibe is currently progressing its Phase 2B study to validate the effectiveness of the drug in reducing osteoarthritis pain and establish the proper dose for Phase 3 development. The study involves 360 patients with osteoarthritis of the knee who will be randomized and placed in four groups: one taking a placebo, with the remaining three taking either 150, 200 or 250 milligrams of ATB-346.

According to CEO Dan Legault, a successful outcome of this phase of the trial will represent a major inflection point for the company as it positions itself for global partner development.

Initial results are expected during summer 2019.

Robust product pipeline

The biotech company has a strong pipeline of drugs in development targeting pain and regenerative medicine.

In addition to ATB-346, Antibe has two other drugs in development. ATB 352 is a derivative of ketoprofen, a potent NSAID for acute pain. Its intended use will be in competition with strong opioids such as fentanyl and oxycontin. The company expects to conclude pre-clinical studies in 2020.

Also in the pipeline is ATB-340, an anti-thrombotic for the prevention of cardiovascular disease and cancer chemoprevention. Preclinical studies are expected to commence in 2020.

Antibe also operates two commercial subsidiaries that contribute to the company’s revenue profile. Citagenix Inc sells and markets tissue regenerative products for the dental biologics market, adding a C$10 million revenue base for the company. BMT Medizintechnik GmbH designs, manufactures and markets over 10,000 surgical instruments in Europe, the Americas, the Middle East and Asia.

'Sound science'

Prominent investors are taking notice of the work Antibe is doing to disrupt the global NSAID market. In a recent interview with BNN Bloomberg in Toronto, Robert McWhirter, president and portfolio manager at Selective Asset Management named Antibe Therapeutics as one of his top picks.

“We think that this is a very sound science for delivering a drug with a huge need in the marketplace and being able to offer a stomach and intestine-friendly solution with Antibe’s product is very compelling,” he said in the interview.

If all goes according to plan, Antibe’s hydrogen sulfide technology could be a game-changing medical advance in the safe treatment of pain and inflammation.

View full ATE profile View Profile

Antibe Therapeutics Timeline

Related Articles

Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use